Bone Biologics (BBLGW) Retained Earnings (2010 - 2026)

Bone Biologics (BBLGW) has reported Retained Earnings for 17 consecutive years, with $93.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Retained Earnings changed 0.24% year-over-year to $93.6 million in Q2 2026; TTM through Jun 2026 was $93.6 million, a 0.24% change from a year earlier, with the FY2025 full-year figure at $93.5 million, up 5.65% from the prior year.
• Retained Earnings was $93.6 million for Q2 2026 at Bone Biologics, roughly flat from $93.5 million in the prior quarter.
• Over five years, Retained Earnings peaked at $93.6 million in Q2 2026 and troughed at $77.2 million in Q1 2022.
• A 5-year average of $85.2 million and a median of $85.4 million in 2024 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings jumped 211.4% in 2022 and gained 0.24% in 2026, its largest moves.
• Over 5 years, Retained Earnings stood at $77.9 million in 2022, then advanced by 7.58% to $83.8 million in 2023, then grew by 5.6% to $88.5 million in 2024, then rose by 5.65% to $93.5 million in 2025, then gained by 0.09% to $93.6 million in 2026.
• The last three Retained Earnings figures came in at $93.6 million (Q2 2026), $93.5 million (Q4 2025), and $93.5 million (Q3 2025), per Business Quant data.